CADL (Candel Therapeutics) Current Accrued Expense: $6.98 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CADL Candel Therapeutics Inc CADL
21 GF Score
Price $13.27
! 3 Warning Signs
View Full Analysis

What is Candel Therapeutics Current Accrued Expense?

Candel Therapeutics CADL -2.28% 21 Current Accrued Expense is $6.98 Mil as of Jun. 2026. GuruFocus rates CADL with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Candel Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was $6.98 Mil.

Candel Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 ($7.33 Mil) to Mar. 2026 ($3.47 Mil) but then increased from Mar. 2026 ($3.47 Mil) to Jun. 2026 ($6.98 Mil).

Candel Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($4.36 Mil) to Dec. 2024 ($5.11 Mil) and increased from Dec. 2024 ($5.11 Mil) to Dec. 2025 ($7.33 Mil).

Candel Therapeutics Current Accrued Expense Related Terms

Candel Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Candel Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Candel Therapeutics Current Accrued Expense Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 3.44 4.72 4.36 5.11 7.33

Candel Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.32 5.15 7.33 3.47 6.98
CADL
21GF Score
Candel Therapeutics Inc CADL
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Candel Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $6.98 Mil mean?
Candel Therapeutics (CADL) has a Current Accrued Expense of $6.98 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Candel Therapeutics and its competitors.
Is Candel Therapeutics' Current Accrued Expense too high?
Candel Therapeutics' current Current Accrued Expense is $6.98 Mil. Overall, Candel Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' Current Accrued Expense compare to NGNE and CTMX?
Candel Therapeutics' Current Accrued Expense of $6.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Candel Therapeutics and its competitors. Candel Therapeutics's current Current Accrued Expense is $6.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current Current Accrued Expense of $6.98 Mil. The current Current Accrued Expense is $6.98 Mil. Candel Therapeutics' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current Current Accrued Expense is $6.98 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Candel Therapeutics Business Description

Address 117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
21GF Score

Get the complete analysis for CADL

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.27
Price